Business · 27/10/2021Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for XENLETA Injection New Drug Application
Summary
The US Food and Drug Administration has officially set a review period for XENLETA injection's new drug application, following a request from the U.S. Patent and Trademark Office to extend a patent related to the human drug product.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →